Development and characterization of influenza M2 ectodomain and/or HA stalk-based DC-targeting vaccines for different influenza infections
Yao, X.; Olukitibi, T.; Ao, Z.; Azizi, H.; Mahmoudi, M.; Coombs, K.; Kobasa, D.; Kobinger, G.
Show abstract
A universal influenza vaccine is required for broad protection against influenza infection. Here, we revealed the efficacy of novel influenza vaccine candidates based on Ebola glycoprotein (EboGP) DC-targeting domain (E{Delta}M) fusion protein technology. We fused influenza hemagglutinin stalk (HAcs) and extracellular matrix protein (M2e) or four copies of M2e (referred to as tetra M2e (tM2e)) with E{Delta}M to generate E{Delta}M-HM2e or E{Delta}M-tM2e, respectively, and revealed that E{Delta}M facilitates DC/macrophage targeting in vitro. In a mouse study, E{Delta}M-HM2e- or E{Delta}M-tM2e-pseudotyped viral particles (PVPs) induced significantly higher titers of anti-HA and/or anti-M2e antibodies. We also developed recombinant vesicular stomatitis virus (rVSV)-E{Delta}M-HM2e and rVSV-E{Delta}M-tM2e vaccines that resulted in rapid and potent induction of HA and/or M2 antibodies in mouse sera and mucosa. Importantly, vaccination protects mice from influenza H1N1 and H3N2 challenges. Taken together, our study suggests that recombinant rVSV-E{Delta}M-HM2e and rVSV-E{Delta}M-tM2e are efficacious and protective universal vaccines against influenza.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Single immunization with recombinant ACAM2000 vaccinia viruses expressing the spike and the nucleocapsid proteins protect hamsters against SARS-CoV-2 caused clinical disease 96%
- Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins 96%
- Optimizing the live attenuated influenza A vaccine backbone for high-risk patient groups 95%
Similar papers in this journal
- A bacteriophage-based, highly efficacious, needle and adjuvant-free, mucosal COVID-19 vaccine 96%
- Surface-modified measles vaccines encoding oligomeric, fusion-stabilized SARS-CoV-2 spike glycoproteins bypass measles seropositivity, boosting neutralizing antibody responses to omicron and historical variants. 95%
- The African Swine Fever Virus gene MGF_360-4L inhibits interferon signaling by recruiting mitochondrial selective autophagy receptor SQSTM1 degrading MDA5 antagonizing innate immune responses 95%
Similar papers in this journal
- Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates 96%
- Epigraph Hemagglutinin Vaccine Induces Broad Cross-reactive Immunity Against Swine H3 Influenza Virus 96%
- SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 elicits immunogenicity in baboons and protection in mice 95%
Similar papers in this journal
- Oral immunization with rVSV bivalent vaccine elicits protective immune responses, including ADCC, against both SARS-CoV-2 and Influenza A viruses 98%
- Soluble Spike DNA vaccine provides long-term protective immunity against SAR-CoV-2 in mice and nonhuman primates 96%
- Cold-adapted live attenuated SARS-CoV-2 vaccine completely protects human ACE2 transgenic mice from SARS-CoV-2 infection 96%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.